Nan Chen

4.5k total citations · 1 hit paper
143 papers, 2.9k citations indexed

About

Nan Chen is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Nan Chen has authored 143 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Pulmonary and Respiratory Medicine, 25 papers in Molecular Biology and 23 papers in Oncology. Recurrent topics in Nan Chen's work include Lung Cancer Diagnosis and Treatment (21 papers), Phytochemicals and Antioxidant Activities (13 papers) and Lung Cancer Treatments and Mutations (13 papers). Nan Chen is often cited by papers focused on Lung Cancer Diagnosis and Treatment (21 papers), Phytochemicals and Antioxidant Activities (13 papers) and Lung Cancer Treatments and Mutations (13 papers). Nan Chen collaborates with scholars based in China, United States and Canada. Nan Chen's co-authors include Wei‐Cai Zeng, Qiang He, Haoxiang Gao, Shaodong Hong, Jianhua Zhan, Shiyang Kang, Wenfeng Fang, Yan Huang, Tao Qin and Yaxiong Zhang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Nan Chen

133 papers receiving 2.9k citations

Hit Papers

Upregulation of PD-L1 by EGFR Activation Mediates the Imm... 2015 2026 2018 2022 2015 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
    2015 534 citations Nan Chen, Wenfeng Fang et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nan Chen China 28 1.2k 769 436 284 252 143 2.9k
Linlin Wang China 28 411 0.3× 570 0.7× 990 2.3× 369 1.3× 368 1.5× 174 2.6k
Yongyue Wei China 27 572 0.5× 380 0.5× 808 1.9× 257 0.9× 208 0.8× 182 2.7k
Kyunga Kim South Korea 30 709 0.6× 674 0.9× 629 1.4× 863 3.0× 157 0.6× 289 4.2k
James C. Boyd United States 38 688 0.6× 576 0.7× 854 2.0× 622 2.2× 113 0.4× 103 4.7k
Lyle D. Broemeling United States 39 961 0.8× 621 0.8× 469 1.1× 616 2.2× 170 0.7× 110 4.5k
Henrik Rasmussen United States 41 1.4k 1.1× 748 1.0× 1.6k 3.7× 1.1k 3.8× 361 1.4× 133 5.7k
Feng Xu China 32 517 0.4× 333 0.4× 1.2k 2.8× 566 2.0× 316 1.3× 283 4.0k
Jianrong Zhang China 26 431 0.3× 400 0.5× 626 1.4× 411 1.4× 146 0.6× 137 2.3k
Hyung Woo Kim South Korea 29 342 0.3× 275 0.4× 373 0.9× 236 0.8× 96 0.4× 227 2.6k
Tong Meng China 25 564 0.5× 470 0.6× 1.1k 2.4× 327 1.2× 234 0.9× 126 3.2k

Countries citing papers authored by Nan Chen

Since Specialization
Citations

This map shows the geographic impact of Nan Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nan Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nan Chen more than expected).

Fields of papers citing papers by Nan Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nan Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nan Chen. The network helps show where Nan Chen may publish in the future.

Co-authorship network of co-authors of Nan Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Nan Chen. A scholar is included among the top collaborators of Nan Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nan Chen. Nan Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Shubeck, Sarah P., et al.. (2025). Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US. JAMA Network Open. 8(2). e2460243–e2460243. 3 indexed citations
3.
4.
Xiao, Peng, Haiyan Huang, Hanshu Zhao, et al.. (2024). Edaravone dexborneol protects against cerebral ischemia/reperfusion-induced blood-brain barrier damage by inhibiting ferroptosis via activation of nrf-2/HO-1/GPX4 signaling. Free Radical Biology and Medicine. 217. 116–125. 31 indexed citations
5.
Shulman, David S., Kelly Klega, Nan Chen, et al.. (2024). Prospective evaluation of pre-treatment ctDNA burden in localized osteosarcoma to identify patients with inferior outcomes: A report from the LEOPARD study.. Journal of Clinical Oncology. 42(16_suppl). 11510–11510. 1 indexed citations
6.
Xia, Hao, Mei Li, Nan Chen, et al.. (2024). CD137 Signaling Mediates Pulmonary Artery Endothelial Cell Proliferation Under Hypoxia By Regulating Mitochondrial Dynamics. Journal of Cardiovascular Translational Research. 17(4). 859–869. 1 indexed citations
7.
8.
Chen, Nan, Haoxiang Gao, Qiang He, & Wei‐Cai Zeng. (2023). Insight into property, function, and digestion of potato starch modified by phenolic compounds with varying structures. Journal of Food Science. 88(3). 962–976. 14 indexed citations
9.
Campbell, Kevin, Nan Chen, Kerri L. Cavanaugh, et al.. (2023). Phase 1 study of cabozantinib in combination with topotecan–cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma. Pediatric Blood & Cancer. 70(12). e30681–e30681. 3 indexed citations
10.
Chen, Nan, Haoxiang Gao, Qiang He, & Wei‐Cai Zeng. (2023). Potato Starch-Based Film Incorporated with Tea Polyphenols and Its Application in Fruit Packaging. Polymers. 15(3). 588–588. 31 indexed citations
11.
Lai, Fenghua, et al.. (2023). Pancreatic-derived factor predicts remission of impaired glucose tolerance women with history of gestational diabetes. Diabetes Research and Clinical Practice. 204. 110892–110892. 3 indexed citations
12.
Xiong, Ying & Nan Chen. (2022). Study on the Dynamic Sand Carrying Capacity and Large - Scale Physical Simulation Cracking Performance of Medium and Low Viscosity Slick Water. International Journal of Science and Research (IJSR). 11(8). 80–86. 1 indexed citations
13.
Chen, Nan, et al.. (2022). Inhibition Effect and Molecular Mechanism of Tea Polyphenols on the α-Amylase. SHILAP Revista de lepidopterología. 1 indexed citations
14.
Chen, Lin, et al.. (2022). Effects of different phenolic compounds on the interfacial behaviour of casein and the action mechanism. Food Research International. 162(Pt B). 112110–112110. 27 indexed citations
15.
Hou, Xiao Hua, Song Gao, Qin Li, et al.. (2021). Intracounty modeling of COVID-19 infection with human mobility: Assessing spatial heterogeneity with business traffic, age, and race. Proceedings of the National Academy of Sciences. 118(24). 101 indexed citations
16.
Wang, Yinkui, Ziyu Li, Fei Shan, et al.. (2018). [Current status of diagnosis and treatment of early gastric cancer in China--Data from China Gastrointestinal Cancer Surgery Union].. PubMed. 21(2). 168–174. 26 indexed citations
17.
Chen, Nan, Wenfeng Fang, Jianhua Zhan, et al.. (2015). Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. Journal of Thoracic Oncology. 10(6). 910–923. 534 indexed citations breakdown →
18.
Li, Xiao & Nan Chen. (2013). Management of Crescentic Glomerulonephritis: What Are the Recent Advances?. Contributions to nephrology. 181. 229–239. 8 indexed citations
19.
Zhang, Wen, Xiaonong Chen, Yongxi Chen, & Nan Chen. (2011). Clinical experience with nadroparin in patients undergoing dialysis for renal impairment. Hemodialysis International. 15(3). 379–394. 4 indexed citations
20.
Wang, Weiming, Feng Liu, & Nan Chen. (2006). [Effects of peroxisome proliferators-activated receptor gamma agonists on transforming growth factor-beta1 and Smads signal pathway: experiment with rat renal fibroblasts].. PubMed. 86(11). 740–4. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Linlin Wang Breakdown of academic impact, for papers by Yongyue Wei Breakdown of academic impact, for papers by Kyunga Kim Breakdown of academic impact, for papers by James C. Boyd Breakdown of academic impact, for papers by Lyle D. Broemeling Breakdown of academic impact, for papers by Henrik Rasmussen Breakdown of academic impact, for papers by Feng Xu Breakdown of academic impact, for papers by Jianrong Zhang Breakdown of academic impact, for papers by Hyung Woo Kim Breakdown of academic impact, for papers by Tong Meng
Rankless by CCL
2026